Related Experiment Video
Updated: Jan 11, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Long-acting Cabotegravir/Rilpivirine for Treatment of HIV During Pregnancy: A Case Series
Shawnalyn W Sunagawa1,2, Carly Cloud Floyd3, Sara H Bares4
1Department of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Abstract:
We present pharmacokinetic data on long-acting cabotegravir/rilpivirine (LA CAB/RPV) from two patients during their second and third trimesters. Monthly LA CAB/RPV dosing maintained concentrations above the proposed efficacy thresholds while bimonthly dosing resulted in subtherapeutic RPV concentrations. This highlights the potential of monthly LA CAB/RPV dosing in pregnancy.
Related Concept Videos
Retrovirus Life Cycles
Teratogenicity
Retroviruses
Subviral Agents

